Kairos Pharma (KAPA) announces the addition of Huntsman Cancer Institute in Salt Lake City, Utah for the Phase 2 clinical trial for ENV105 for castrate-resistant prostate cancer patients.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
